This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thompson, P. M. Articles by White, P. S. Search for Related Content PubMed PubMed Citation Articles by Thompson, P. M. Articles by White, P. S.

Homozygous Deletion of CDKN2A (p16^INK4a/p14^ARF) but not within 1p36 or at Other Tumor Suppressor Loci in Neuroblastoma¹

Division of Oncology [P. M. T., J. M. M., M. D. H., G. M. B., P. S. W.], The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104; Department of Pediatrics [J. M. M., M. D. H., G. M. B., P. S. W.], University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104; Division of Hematology-Oncology, Children’s Hospital Los Angeles, Los Angeles, California 90027 [R. C. S., C. P. R.]; and Department of Pediatrics, University of Southern California School of Medicine, Los Angeles, California 90027 [R. C. S., C. P. R.]

Loss of heterozygosity of several specific genomic regions is frequently observed in neuroblastoma tumors and cell lines, but homozygous deletion (HD) is rare, and no neuroblastoma tumor suppressor gene (TSG) has yet been identified. We performed a systematic search for HD, indicative of a disrupted TSG, in a panel of 46 neuroblastoma cell lines. An initial search focused on a well-characterized consensus region of hemizygous deletion at 1p36.3, which occurs in 35% of primary neuroblastomas. Each cell line was screened with 162 1p36 markers, for a resolution of 13 kb within the consensus 1p36.3 deletion region and 350 kb throughout the remainder of 1p36. No HDs were detected. This approach was expanded to survey 21 known TSGs, specifically targeting intragenic regions frequently inactivated in other malignancies. HD was detected only at the CDKN2A (p16^INK4a/p14^ARF) gene at 9p21 and was observed in 4 of 46 cell lines. The observed region of HD included all exons of both CDKN2A and the closely linked CDKN2B (p15^INK4b) gene for cell lines LA-N-6 and CHLA-174, all exons of CDKN2A but none of CDKN2B for CHLA-179, and only 104 bp within CDKN2A exon 2 for CHLA-101. All four deletions are predicted to inactivate the coding regions of both p16^INK4a and p14^ARF. HD was observed in corresponding primary tumor samples for CHLA-101 and CHLA-174 but was not present in constitutional samples. These results suggest that for neuroblastoma, large HDs do not occur within 1p36, most known TSGs are not homozygously deleted, and biallelic inactivation of CDKN2A may contribute to tumorigenicity in a subset of cases.

This article has been cited by other articles:

				M. D. Hogarty, M. D. Norris, K. Davis, X. Liu, N. F. Evageliou, C. S. Hayes, B. Pawel, R. Guo, H. Zhao, E. Sekyere, et al. ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma Cancer Res., December 1, 2008; 68(23): 9735 - 9745. [Abstract] [Full Text] [PDF]

				T. Fujita, J. Igarashi, E. R. Okawa, T. Gotoh, J. Manne, V. Kolla, J. Kim, H. Zhao, B. R. Pawel, W. B. London, et al. CHD5, a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas J Natl Cancer Inst, July 2, 2008; 100(13): 940 - 949. [Abstract] [Full Text] [PDF]

				T. Van Maerken, F. Speleman, J. Vermeulen, I. Lambertz, S. De Clercq, E. De Smet, N. Yigit, V. Coppens, J. Philippe, A. De Paepe, et al. Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma Cancer Res., October 1, 2006; 66(19): 9646 - 9655. [Abstract] [Full Text] [PDF]

				J. Carr, E. Bell, A. D.J. Pearson, U. R. Kees, H. Beris, J. Lunec, and D. A. Tweddle Increased Frequency of Aberrations in the p53/MDM2/p14ARF Pathway in Neuroblastoma Cell Lines Established at Relapse Cancer Res., February 15, 2006; 66(4): 2138 - 2145. [Abstract] [Full Text] [PDF]

				M. Rodolfo, R. Luksch, E. Stockert, Y.-T. Chen, P. Collini, T. Ranzani, C. Lombardo, P. Dalerba, L. Rivoltini, F. Arienti, et al. Antigen-Specific Immunity in Neuroblastoma Patients: Antibody and T-Cell Recognition of NY-ESO-1 Tumor Antigen Cancer Res., October 15, 2003; 63(20): 6948 - 6955. [Abstract] [Full Text] [PDF]

				T. Tajiri, X. Liu, P. M. Thompson, S. Tanaka, S. Suita, H. Zhao, J. M. Maris, G. C. Prendergast, and M. D. Hogarty Expression of a MYCN-interacting Isoform of the Tumor Suppressor BIN1 Is Reduced in Neuroblastomas with Unfavorable Biological Features Clin. Cancer Res., August 1, 2003; 9(9): 3345 - 3355. [Abstract] [Full Text] [PDF]